Blood Component Therapy and Dosing

Blood component therapy is the practice of transfusing the specific part of blood a patient lacks — red cells, platelets, plasma, or cryoprecipitate — rather than whole blood. Modern transfusion separates each donation into components so that each can be stored optimally and given for a defined indication. The evidence underpinning when to transfuse, captured in restrictive-versus-liberal threshold trials and the resulting AABB guidelines, is the conceptual core of this topic.

Definition

Blood component therapy is the selective transfusion of a separated blood component to correct a specific deficit; a transfusion threshold is the trigger — most often a haemoglobin level for red cells — at which transfusion is considered, compared across studies as restrictive versus liberal strategies.

Scope

This topic covers the rationale for component separation, the principal components and their general purposes, the concept of transfusion thresholds, and the body of trial evidence and guidelines that distinguish restrictive from liberal strategies. It explains how the evidence base is organised and what it shows at a population level. It deliberately omits individualised dosing rules and treatment instructions; specific dosing and patient decisions rest with treating clinicians and local protocols.

Core questions

• Why is blood separated into components rather than transfused whole?
• Which deficit does each major component address?
• What does trial evidence show when restrictive and liberal transfusion thresholds are compared?
• How do current AABB guidelines frame the decision to transfuse red cells?

Key concepts

• Component separation
• Packed red blood cells
• Platelet concentrates
• Fresh frozen plasma
• Cryoprecipitate
• Transfusion threshold (haemoglobin trigger)
• Restrictive versus liberal strategy
• Single-unit transfusion principle

Mechanisms

A whole-blood donation is separated by centrifugation into red cells, platelets, and plasma, with cryoprecipitate prepared from plasma; each component is then stored under conditions that preserve its function. Red cells are transfused to raise oxygen-carrying capacity, platelets to support haemostasis when counts or function are low, plasma to replace multiple coagulation factors, and cryoprecipitate to supply fibrinogen and selected factors. The central evidence question is the threshold for transfusion: randomised trials comparing restrictive triggers with liberal ones, synthesised in systematic reviews, have generally found that restrictive strategies are not inferior for many stable patient groups, which is reflected in guideline recommendations (Carson et al., 2012; Carson et al., 2017; Carson et al., 2023).

Clinical relevance

Component therapy and threshold evidence shape how blood is used across medicine and surgery, and a move toward restrictive triggers has reduced unnecessary exposure to allogeneic blood without compromising outcomes in many settings. This entry summarises that evidence and the structure of the guidelines at a reference level; it is explicitly non-prescriptive and does not provide haemoglobin targets, component doses, or treatment directions for any individual patient, which depend on clinical context and current local guidance (Carson et al., 2023).

Epidemiology

Red cells are the most commonly transfused component, and large multicentre trials in critical care, cardiac and orthopaedic surgery, and gastrointestinal bleeding have repeatedly compared restrictive and liberal thresholds. Their synthesis has driven a broad practice shift toward more restrictive transfusion in haemodynamically stable adults, a change documented in successive AABB guidelines (Carson et al., 2012; Carson et al., 2023).

History

Early transfusion used whole blood, but the mid-twentieth-century development of plastic collection systems and centrifugation made component separation routine, allowing each part of a donation to serve a different patient and indication. From the 1990s onward, landmark randomised trials — beginning with critical-care studies of restrictive versus liberal transfusion — and their Cochrane synthesis reframed transfusion as a threshold decision, and the AABB codified the findings in clinical practice guidelines updated in 2016 and again in 2023 (Carson et al., 2012; Carson et al., 2023).

Debates

Where should the red-cell transfusion threshold sit, and for whom?

Restrictive strategies are supported for many stable patients, but the optimal threshold in specific groups — for example those with acute coronary syndromes — has remained an active question that successive trials and guideline updates continue to refine.

Key figures

• Jeffrey Carson
• Paul Hebert
• Simon Stanworth
• Aaron Tobian

Seminal works

• carson-2012-cochrane
• carson-2017
• carson-2023

Frequently asked questions

Why is blood given as separate components rather than as whole blood?

Separating a donation into red cells, platelets, plasma, and cryoprecipitate lets each component be stored under ideal conditions and transfused only to patients who need that specific part, which makes better use of donated blood and targets the patient's actual deficit.

What does a 'restrictive' transfusion strategy mean?

A restrictive strategy uses a lower haemoglobin trigger for transfusing red cells than a liberal strategy. Trial evidence and AABB guidelines indicate restrictive thresholds are appropriate for many stable patients, though specific targets are a clinical decision and are not given here.